;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Ampio subsidiary Vyrix files for IPO

    The Vyrix Pharmaceutical Inc. subsidiary of Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) filed to raise up to $28.8 million in an IPO on NYSE MKT. Aegis Capital and Fordham are underwriters. Ampio carved off its sexual …

    Published on 4/17/2014
  • FINANCIAL NEWS: Fertility play Nora raises $18 million in series B

    Nora Therapeutics Inc. (Palo Alto, Calif.) raised $18 million in a series B round led by new investor Novo A/S. Existing investors Burrill; Prospect Venture Partners; Rho Ventures; and Vivo Capital also participated. …

    Published on 4/17/2014
  • FINANCIAL NEWS: Heart Metabolics secures $20 million in series A

    Heart Metabolics Ltd. (Dublin, Ireland) raised an undisclosed amount in the first tranche of a planned $20 million series A round from venBio; Seroba Kernal Life Sciences; Brandon Capital Partners; and AshHill. Heart …

    Published on 4/17/2014
  • FINANCIAL NEWS: AMD company Iconic closes $20 million round

    Iconic Therapeutics Inc. (Atlanta, Ga.) closed a $20 million series B round from new investors MPM Capital; Lundbeckfond Ventures; and H.I.G. BioVentures. Iconic is planning a Phase II trial of hI-con1 to treat wet age-…

    Published on 4/16/2014
  • FINANCIAL NEWS: ForSight Vision5 raises $15 million in series C

    ForSight Vision5 Inc. (Menlo Park, Calif.) raised $15 million in a series C round led by new investor H.I.G. BioVentures. Existing investors Morgenthaler Ventures; Versant Ventures; Technology Partners; and Delphi …

    Published on 4/16/2014
  • FINANCIAL NEWS: Foundation Medicine withdraws follow-on

    Pharmacogenetics company Foundation Medicine Inc. (NASDAQ:FMI) withdrew a proposed follow-on, citing market conditions. The company filed to raise $150 million in the offering last month, when its share price was $39.43…

    Published on 4/16/2014
  • FINANCIAL NEWS: Microlin Bio sets IPO range

    Microlin Bio Inc. (New York, N.Y.) amended its IPO on NASDAQ and now plans to sell 2.7 million shares at $10-$12. At the $11 midpoint, the company would raise $30 million and be valued at $75.1 million. Brean Capital …

    Published on 4/16/2014
  • FINANCIAL NEWS: Vital raises $54 million in IPO

    Liver disease company Vital Therapies Inc. (NASDAQ:VTL) raised $54 million through the sale of 4.5 million shares at $12 in an IPO underwritten by BofA Merrill Lynch; Credit Suisse; William Blair; and Canaccord. The …

    Published on 4/16/2014
  • FINANCIAL NEWS: Wilson's disease play secures $40 million

    Wilson Therapeutics AB (Stockholm, Sweden) raised an undisclosed amount in a tranched $40 million series B round co-led by new investors Abingworth and MVM Life Science Partners. Existing investor HealthCap also …

    Published on 4/16/2014
  • FINANCIAL NEWS: Angion files for IPO

    Angion Biomedica Corp. (Uniondale, N.Y.) filed to raise up to $34.5 million in an IPO on NASDAQ underwritten by Aegis Capital. Angion's BB3 is in Phase II testing to treat delayed graft function in renal transplant …

    Published on 4/15/2014
  • FINANCIAL NEWS: Gene therapy play AAVLife secures $12 million

    AAVLife (Paris, France) secured $12 million in a series A round led by new investor Versant Ventures. New investor French National Institute of Health and Medical Research (Inserm) Transfert Initiative also participated…

    Published on 4/15/2014
  • FINANCIAL NEWS: J&J reports first simeprevir sales

    Johnson & Johnson (NYSE:JNJ) reported 1Q14 earnings on Tuesday, including $354 million in worldwide sales of Olysio simeprevir in the HCV drug's first full quarter of sales. U.S. sales of the drug were $291 million for …

    Published on 4/15/2014
  • FINANCIAL NEWS: Quotient lowers IPO range

    Transfusion diagnostics company Quotient Ltd. (Penicuik, U.K.) amended its planned IPO on NASDAQ to lower the proposed price range. The company now plans to sell 5 million shares at $9-$11. At the $10 midpoint, Quotient…

    Published on 4/15/2014
  • FINANCIAL NEWS: The Column Group targeting $250 million for second fund

    Biotech VC firm The Column Group has raised $175.9 million of a planned $250 million for its second fund, according to an SEC filing. The firm could not be reached for details in time for publication. According to its …

    Published on 4/15/2014
  • FINANCIAL NEWS: TxCell up slightly in trading debut

    Inflammatory and autoimmune disease play TxCell S.A. (Euronext:TXCL) was up EUR 0.08 to EUR 5.66 on its first day of trading Monday. The company raised EUR 16.2 million ($22.2 million) through the sale of 2.9 million …

    Published on 4/14/2014
  • FINANCIAL NEWS: Regado raises $60 million in follow-on

    Regado Biosciences Inc. (NASDAQ:RGDO) raised $60 million through the sale of 10 million shares at $6 in a follow-on underwritten by Jefferies; Deutsche Bank; and Cowen. Regado proposed to raise up to $60 million in the …

    Published on 4/11/2014
  • FINANCIAL NEWS: Relypsa raises $88 million in follow-on

    Relypsa Inc. (NASDAQ:RLYP) raised $88 million through the sale of 3.6 million shares at $24.50 in a follow-on underwritten by Morgan Stanley; BofA Merrill Lynch; Cowen; Stifel; and Wedbush PacGrow. Relypsa proposed to …

    Published on 4/11/2014
  • FINANCIAL NEWS: TxCell raises EUR 16.2 million in IPO

    Inflammatory and autoimmune disease play TxCell S.A. (Euronext:TXCL) raised EUR 16.2 million ($22.2 million) through the sale of 2.9 million shares at EUR 5.58 in an IPO. The price -- at the low end of the EUR 5.58-EUR …

    Published on 4/11/2014
  • FINANCIAL NEWS: Adamas raises $48 million in IPO

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) raised $48 million through the sale of 3 million shares at $16 in an IPO underwritten by Credit Suisse; Piper Jaffray; William Blair; and Needham. The price -- at the low end of…

    Published on 4/10/2014
  • FINANCIAL NEWS: Agios planning $75 million follow-on

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO) proposed to raise $75 million in a follow-on underwritten by JPMorgan and Goldman Sachs. The proposed offering comes after Agios gained $9.87 (28%) to $45.35 on Monday after …

    Published on 4/10/2014
  • FINANCIAL NEWS: Cerulean raises $59.5 million in IPO

    Cerulean Pharma Inc. (NASDAQ:CERU) raised $59.5 million in an IPO through a bumped-up number of shares below its proposed price range. The company sold 8.5 million shares at $7, which values Cerulean at $133.1 million. …

    Published on 4/10/2014
  • FINANCIAL NEWS: CNS play Minerva files for IPO

    Minerva Neurosciences Inc. (Cambridge, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by Jefferies; Baird; and JMP Securities. Next half, Minerva plans to start a Phase IIb trial of MIN-101 to …

    Published on 4/10/2014
  • FINANCIAL NEWS: NuCana raises $57 million in series B

    NuCana BioMed Ltd. (Edinburgh, U.K.) raised $57 million in a series B round led by new investor Sofinnova Ventures. Existing investors Sofinnova Partners; Morningside Ventures; Alida Capital International; and the …

    Published on 4/10/2014
  • FINANCIAL NEWS: Pain play Spinifex secures $45 million series C

    Spinifex Pharmaceuticals Pty. Ltd. (South Yarra, Australia) raised an undisclosed amount in a tranched $45 million series C round led by new investor Novo A/S. New investor Canaan Partners also participated along with …

    Published on 4/10/2014
  • FINANCIAL NEWS: CymaBay to raise $30 million, move to NASDAQ

    CymaBay Therapeutics Inc. (OTCQB:CYMA) said it plans to raise up to $30 million in a follow-on and move its listing to NASDAQ. Cowen; Stifel; Roth Capital Partners; and National Securities are underwriters. CymaBay (…

    Published on 4/9/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993